Q2 2017 13F Holders as of 6/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
124M
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
121M
-
Shares change
-
+6.74M
-
Total reported value, excl. options
-
$1.56B
-
Value change
-
+$86.2M
-
Put/Call ratio
-
0.12
-
Number of buys
-
97
-
Number of sells
-
-55
-
Price
-
$12.82
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2017
196 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2017.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 121M shares
of 124M outstanding shares and own 98.24% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.3M shares), BlackRock Inc. (11.6M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (10.6M shares), VANGUARD GROUP INC (9.6M shares), BB BIOTECH AG (8.27M shares), First Eagle Investment Management, LLC (7.39M shares), FMR LLC (5.49M shares), Invesco Ltd. (4.44M shares), SENZAR ASSET MANAGEMENT, LLC (4.09M shares), and STATE STREET CORP (3.67M shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.